Planned intervention: On Wednesday April 3rd 05:30 UTC Zenodo will be unavailable for up to 2-10 minutes to perform a storage cluster upgrade.
Published September 29, 2015 | Version v1
Journal article Restricted

A Telomerase Peptide Vaccination simulated poly-chemo mimotopic pharmacological structure Combined with Temozolomide as a novel in silico promising anti-cancer drug-like agent in Stage IV Melanoma Patients generated by the BiogenetoligandorolTM based parallel web service for structural proteome-wide multi-targeted ligand-binding conserved binding pharmacophoric site comparison.

  • 1. Biogenea Pharmaceuticals Ltd

Description

immune response, and clinicalresponse in melanoma patients after combined therapy with temozolomide and the telomerase peptide vaccine GV1001 in previous GV1001 trials showed immune responses in approximately 60% of lung orpancreatic cancer patients. Previous Experimental Studies Twenty-five subjects with advanced stage IV melanoma (M1B or M1C) received concomitant temozolomide and GV1001. Temozolomide was administered 200 mg/m2 orally for 5 daysevery fourth week, and GV1001 as eight injections over 11 weeks. Immune response was evaluated bydelayed type hypersensitivity, T-cell proliferation, and cytokine assays. The immunologic responders continued monthly vaccination. Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments. Proc. Natl Acad. Sci. USA, 105, 5441–5446]. A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery. Bioinformatics, 25, i305–i312.]. These algorithms have been extensively benchmarked and shown to outperform most existing algorithms. Moreover, several predictions resulting from SMAP-WS have been validated experimentally. Thus far SMAP-WS has been applied to predict drug side effects, and to repurpose existing drugs for new indications. SMAP-WS provides both a user-friendly web interface and programming API for scientists to address a wide range of compute intense questions in biology and drug discovery. Here, in Biogenea we have for the first generated an in silico Telomerase Peptide mimotopic poly-chemo structure simulator eith promising clinical results in Stage IV Melanoma Patients when combined with Temozolamide using the BiogenetoligandorolTM and the SMAP-WS. A parallel web service for structural proteome-wide ligand-binding site comparison.

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.